Emergent BioSolutions (EBS) Shares Outstanding (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Shares Outstanding (Entity) of $61.4 million for Q1 2026, up 2.16% year-over-year from $60.1 million in Q1 2025, and up 0.82% quarter-over-quarter from $60.9 million in Q4 2025.
Emergent BioSolutions (EBS) Shares Outstanding (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $61.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.16% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (up 2.16% YoY), while the FY2025 annual figure was $60.9 million, up 1.67% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $61.4 million, up from $60.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $61.4 million in Q1 2026, with the low at $55.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $58.0 million (2024), against an average of $58.2 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) climbed 0.91% in 2022, then increased 4.01% in 2024.
- Emergent BioSolutions' Shares Outstanding (Entity) stood at $55.7 million in 2022, then advanced by 3.77% to $57.8 million in 2023, then gained by 3.63% to $59.9 million in 2024, then increased by 1.67% to $60.9 million in 2025, then advanced by 0.82% to $61.4 million in 2026.
- Business Quant data shows EBS's Shares Outstanding (Entity) at $61.4 million in Q1 2026, $60.9 million in Q4 2025, and $60.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 51.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.60 Mn |
| Mar 31, 2026 | 51.90 Mn |
| Dec 31, 2025 | 53.50 Mn |
| Sep 30, 2025 | 53.20 Mn |
| Jun 30, 2025 | 54.20 Mn |
| Mar 31, 2025 | 54.40 Mn |
| Dec 31, 2024 | 53.00 Mn |
| Sep 30, 2024 | 53.10 Mn |
| Jun 30, 2024 | 52.60 Mn |
| Mar 31, 2024 | 52.20 Mn |
| Dec 31, 2023 | 51.20 Mn |
| Sep 30, 2023 | 51.80 Mn |
| Jun 30, 2023 | 50.70 Mn |
| Mar 31, 2023 | 50.20 Mn |
| Dec 31, 2022 | 50.10 Mn |
| Sep 30, 2022 | 49.90 Mn |
| Jun 30, 2022 | 50.00 Mn |
| Mar 31, 2022 | 50.70 Mn |
| Dec 31, 2021 | 53.50 Mn |
| Sep 30, 2021 | 53.70 Mn |